Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Company's filing influential in FDA shunt reclass:

This article was originally published in Clinica

Executive Summary

The US FDA has issued a final guidance document that will allow manufacturers of new endolymphatic shunt tubes with valves to file an abbreviated 510(k) rather than a PMA. The initial guidance document, issued last November in conjunction with a proposed rule reclassifying the product from a high risk, class III, device to a medium risk, class II, device would have required manufacturers to submit a full 510(k) notification. But since then E Benson Hood Laboratories has submitted enough new information on the product that the agency has decided to allow companies to use the less complex abbreviated 510(k) regulatory path in the future.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT066323

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel